OrganaBio has opened a new cell processing site in San Diego offering rapid PBMC isolation and cryopreservation, announced the company. The facility aims to improve quality, consistency, and supply chain reliability for these critical cell and gene therapy (CGT) starting materials.
The site enables four-hour processing turnaround, significantly compressing the typical timeline. Fresh peripheral blood mononuclear cells (PBMCs) are isolated and cryopreserved locally, reducing transport stress and cell degradation. This approach targets higher viability and functional recovery for downstream CGT manufacturing.
OrganaBio positions this expansion as a response to growing demand for standardized, high-quality PBMCs. By shortening the isolation-to-cryopreservation window, the company hopes to address variability that has long plagued early-stage cell therapy development. The San Diego location was chosen for proximity to biotech hubs.
For CGT developers, faster, more consistent PBMC sourcing could accelerate preclinical and clinical workflows. The offering may reduce batch failures attributed to poor starting material quality. OrganaBio's network now includes sites in San Diego and other U.S. locations, enhancing geographic coverage.
CounterArgument: Some industry observers caution that local processing alone may not resolve deeper supply chain issues, such as donor-to-donor variability and regulatory complexity across jurisdictions. The impact on cost and scalability at commercial volumes remains unproven.